Fundraising Fox
Cero Therapeutics Holdings
OTC: CEROSouth San Francisco, US · Founded 2021 · Delaware corporation
Find your way into Cero Therapeutics Holdings
Each arrow is one introduction. Sign up to fill in the first one.
Ask RICHARD KING to introduce you to Chris Ehrlich
You →RICHARD · together at Prolynx →Chris
Sign up to find every way you can get introduced to Cero Therapeutics Holdings
- Your email: who you already know at Cero Therapeutics Holdings, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Cero Therapeutics Holdings team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
CERO develops engineered T-cell therapies that combine tumor-clearance mechanisms from both the innate and adaptive immune systems within a single cell. Its CER T-cell platform targets treatments for hematologic malignancies and solid tumors.
Founders & leadership
Board
Reported raises · per SEC filings
Form D private placements$16.4M disclosed across 3 rounds · 2024–2025
▶$5MraisedMay 2025 · 5 investors · PharmaceuticalsRule 506(b)
- Shami PatelDirector
- Kristen PierceExecutive Officer
- Lindsey RolfeDirector
- Kathleen LaPorteDirector
- Andrew Albert KucharchukExecutive Officer
- Chris EhrlichExecutive Officer, Director
- Michael ByrnesDirector
- Brian G. AtwoodDirector
- Offering amount
- $8M
- Amount sold
- $5M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.3MraisedOct 2024 · 13 investors · PharmaceuticalsRule 506(b)
- Kristen PierceExecutive Officer
- Michael ByrnesDirector
- Brian AtwoodDirector
- Lindsey RolfeDirector
- Chris EhrlichExecutive Officer, Director
- Andrew Albert KucharchukExecutive Officer
- Kathleen LaPorteDirector
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- Minimum investment
- $1K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$10.2MraisedFeb 2024 · 46 investors · PharmaceuticalsRule 506(b)
- Lindsey RolfeDirector
- Robyn RapaportDirector
- Michael ByrnesDirector
- Brian AtwoodExecutive Officer, Director
- Offering amount
- $10.2M
- Amount sold
- $10.2M
- Sales commissions
- $1.2M
- Proceeds to insiders
- $227.8K
- Placement agents
- J.V.B. Financial Group, LLC
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Cero Therapeutics Holdings do?
- CERO develops engineered T-cell therapies that combine tumor-clearance mechanisms from both the innate and adaptive immune systems within a single cell. Its CER T-cell platform targets treatments for hematologic malignancies and solid tumors.
- How much funding has Cero Therapeutics Holdings raised?
- Cero Therapeutics Holdings has disclosed $16.4M raised across 3 rounds.
- Where is Cero Therapeutics Holdings headquartered?
- Cero Therapeutics Holdings is headquartered in South San Francisco, US.